New drug duo aims to shrink inoperable lung tumors enough for surgery
NCT ID NCT06706219
First seen Apr 05, 2026 · Last updated Apr 30, 2026 · Updated 4 times
Summary
This study tests a combination of two drugs, sacituzumab tirumotecan and toripalimab, in 50 adults with stage III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if the treatment can shrink tumors enough to allow surgery, and to measure how long the cancer stays under control. Participants will receive the drugs and be monitored for side effects and outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER (STAGE III) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Provincal Tumor Hospital
Changsha, Hunan, 410013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.